Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status Joseph Treat, Chao Hui Huang, Stephen R. Lane, Jeremey Levin Oncologist 2004; 9: 173-181 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the hematologic safety profile of topotecan in patients with relapsed small cell lung cancer. Identify the risk factors for poorer performance status. Discuss the role of topotecan in the management of poor performance status patients with relapsed small cell lung cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 26, 2004 Most Recent Review: Mar. 26, 2004* Most Recent Update: Mar. 26, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.